Scandion Oncology A/S (SCOL) AI Stock Analysis

• Market Cap: kr1.17M
• Dividend Yield: N/A
• Average Volume (3M): 2.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: N/A
• EPS Growth: 57.91%
• Country: SE
• Employees: 4
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 234,761,410
• 10 Day Avg. Volume: 1,890,051
• 30 Day Avg. Volume: 2,543,284
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Scandion Oncology A/S faces significant financial and operational challenges typical of early-stage biotech companies. The lack of revenue and consistent losses are major concerns, compounded by reliance on external funding. Technical indicators suggest weak momentum, and the valuation is constrained by the negative P/E ratio due to ongoing losses. Overall, the stock is high-risk with uncertain prospects, primarily influenced by its financial health and market trends.

Scandion Oncology A/S Business Overview & Revenue Model

Company Description

Scandion Oncology A/S (SCOL) is a biotechnology company specializing in developing innovative treatments to overcome drug resistance in cancer therapy. The company focuses on creating and advancing pharmaceutical solutions that enhance the effectiveness of existing cancer treatments. Scandion Oncology's core product portfolio includes proprietary drug candidates designed to counteract resistance mechanisms in cancer cells, thus improving patient outcomes in oncology sectors.

How the Company Makes Money

Scandion Oncology A/S makes money through the development and commercialization of its drug candidates aimed at reversing cancer drug resistance. The company's revenue model primarily involves research and development collaborations, licensing agreements, and potential milestone payments from pharmaceutical partners. These partnerships can include upfront payments, research funding, and royalties on the sales of successfully marketed drugs. Additionally, Scandion Oncology may receive governmental or institutional grants to support their innovative research efforts. As the company's drug candidates progress through clinical trials and achieve regulatory approvals, these financial streams become crucial in driving growth and sustaining operations.

Scandion Oncology A/S Financial Statement Overview

Summary

Scandion Oncology A/S is experiencing severe financial challenges with no revenue generation and continuous operational losses. The company has a low debt-to-equity ratio, which is somewhat favorable, but the decline in equity and shrinking asset base raise significant liquidity concerns. The negative cash flow situation emphasizes a heavy reliance on external financing, which could be risky if funding sources dry up.

Income Statement

Scandion Oncology A/S shows no revenue generation over the periods, reflecting a developmental stage typical for biotechnology firms. The company has consistent negative EBIT and net income, indicating ongoing operational losses. This lack of revenue and profitability is a significant financial challenge.

Balance Sheet

The company's debt-to-equity ratio is low, suggesting limited leverage, which is favorable. However, the equity base has declined significantly from previous years, and total assets have shrunk, indicating potential liquidity issues. The equity ratio remains modest, but the decline in stockholders' equity is concerning.

Cash Flow

Negative operating cash flow and free cash flow reflect the company's cash burn typical for early-stage biotech firms. Although financing activities have provided some cash inflow, this reliance on external funding is a risk. The cash flow situation highlights the need for sustained financing to support operations.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	205.44K
Gross Profit	0.00	0.00	0.00	0.00	0.00	-11.16M
EBITDA	-39.83M	-45.53M	-80.82M	-56.10M	-22.85M	-15.60M
Net Income	-36.66M	-39.20M	-76.70M	-51.70M	-16.27M	-12.18M
Balance Sheet
Total Assets	18.28M	34.56M	89.40M	116.22M	186.41M	19.90M
Cash, Cash Equivalents and Short-Term Investments	12.69M	26.52M	77.61M	105.71M	5.81M	15.42M
Total Debt	66.00K	499.00K	1.60M	1.22M	316.00K	1.42K
Total Liabilities	10.01M	3.44M	19.07M	11.68M	30.54M	1.56M
Stockholders Equity	8.27M	31.12M	70.33M	104.54M	155.87M	18.34M
Cash Flow
Free Cash Flow	-27.61M	-50.67M	-69.86M	-50.12M	-17.50M	-10.20M
Operating Cash Flow	-27.61M	-50.67M	-69.44M	-49.80M	-17.45M	-9.96M
Investing Cash Flow	263.00K	288.00K	-389.00K	-485.00K	-46.00K	-238.28K
Financing Cash Flow	13.51M	-705.00K	41.73M	150.18M	7.89M	17.95M

Scandion Oncology A/S Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCOL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.01, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.70 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCOL.

Scandion Oncology A/S Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LARK	52 Neutral	kr48.12M	―		79.75%	-94.12%	-25.83%
Sector *	50 Neutral	kr5.44B	12.69	-80.61%	5.08%	37.36%	27.71%
XINT	43 Neutral	kr276.31M	―		―	5303.85%	55.59%
SPRINT	39 Underperform	€53.18M	―	-147.64%	―	30.02%	-3985.71%
LIDDS	37 Underperform	€12.96M	―	-107.11%	―	―	94.98%
SCOL	30 Underperform	kr1.17M	―	-186.04%	―	―	57.91%